Combined inhibition of IL6 and IL8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.
Int J Oncol
; 60(5)2022 May.
Article
in En
| MEDLINE
| ID: mdl-35315502
ABSTRACT
Ovarian cancer is the most lethal gynecological cancer type in the United States. The success of current chemotherapies is limited by chemoresistance and side effects. Targeted therapy is a promising future direction for cancer therapy. In the present study, the efficacy of cotargeting IL6 and IL8 in human ovarian cancer cells by bazedoxifene (Baze) + SCH527123 (SCH) treatment was examined. ELISA, cell viability, cell proliferation, cell migration, cell invasion, western blotting and peritoneal ovarian tumor mouse model analyses were performed to analyze the expression levels of IL6 and IL8, tumor growth, tumor migration and invasion, and the possible pathways of human ovarian cancer cell lines (SKOV3, CAOV3 and OVCAR3) and patientderived OV75 ovarian cancer cells. Each cell line was treated by monotherapy or combination therapy. The results demonstrated that IL6 and IL8 were secreted by human ovarian cancer cell lines. Compared with the DMSO control, the combination of IL6/glycoprotein 130 inhibitor Baze and IL8 inhibitor SCH synergistically inhibited cell viability in ovarian cancer cells. Baze + SCH also inhibited cell migration and invasion, suppressed ovarian tumor growth and inhibited STAT3 and AKT phosphorylation, as well as survivin expression. Therefore, cotargeting the IL6 and IL8 signaling pathways may be an effective approach for ovarian cancer treatment.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Benzamides
/
Selective Estrogen Receptor Modulators
/
Cyclobutanes
/
Indoles
Type of study:
Prognostic_studies
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
Int J Oncol
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article